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Chronic kidney disease: A European perspective. There is an
exponential growth worldwide of patients with end-stage renal
disease (ESRD). Prevalences, outcomes, and underlying causes
of ESRD are relatively well documented through different or-
ganizations. It is, however, clear that a large part of the bad
outcome of ESRD patients is due to deficient follow-up dur-
ing the earlier chronic kidney disease (CKD) stages. Data on
CKD, prevalence of the different stages, and the evolution to
ESRD are rather scant, and available data are conflictive. This
is at least partly due to the lack of an international standard for
measurement of renal function. In addition, there is compiling
evidence that presence of proteinuria, even with a normal renal
function, predisposes to ESRD. Most authors now prefer the
term “kidney injury” rather than “kidney failure” to indicate
people at risk for evolution to ESRD or for complications of
CKD. Detection of these patients at risk is important to imple-
ment measures to slow down progression of CKD and avoid
secondary complications. As it is clear that most of these CKD
patients die before they reach ESRD, it might be that by tak-
ing the necessary preventive measures, the number of ESRD
patients might still further increase exponentially.
The global population of end-stage renal disease
(ESRD) patients treated with renal replacement therapy
(RRT) was estimated to have reached almost 1.7 million
at the end of 2003, and continues to grow at a signifi-
cantly higher rate than the world population. Of the 1.7
million ESRD patients, 1.3 million were undergoing dial-
ysis treatment, and over 300,800 people were living with
kidney transplants.
El Nahas and Bello have recently discussed this global
challenge [1]. In developed countries, it is estimated that
the number of those with ESRD will continue to rise at an
annual rate of around 5% to 8%—a growth driven by an
aging population, increased incidence of diseases involv-
ing renal failure, particularly diabetes mellitus, improved
technology, and better access to treatment.
About 90% of treated ESRD patients come from more
developed countries that can still afford the cost of RRT
[2]. In the United States, the annual expenditure on
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ESRD is estimated to increase to more than US $28 bil-
lion by 2010 [3]. In Europe, dialysis alone takes up about
2% of health care budgets, with only a small proportion
(<0.1%) of the population needing treatment [2].
In numerous countries, mainly in the Western hemi-
sphere, renal registries and other official bodies are valu-
able sources of extensive information on various aspects
of ESRD demographics, treatment practices, and out-
comes.
Table 1 (taken from the European Renal Associa-
tion/European Dialysis and Transplant Association Reg-
istry) shows that the number of new RRT patients in the
25 countries of the European Union can be estimated at
63,000 per year [4]. Currently, there are approximately
360,000 RRT patients in the European Union, with 66%
of them being treated by dialysis and the remainder living
with a functioning graft.
Studies of acceptances to RRT from registry data are
biased, however, because they include only patients be-
lieved to be suitable for treatment, given available health
care resources. A better understanding of the epidemio-
logic characteristics of chronic kidney diseases (CKD) in
the stages before RRT is required to develop strategies
to identify and manage these patients. It is difficult, how-
ever, to get precise epidemiologic data about CKD. This
is mainly because of a tendency to extrapolate data from
the RRT population (assuming that CKD is a precursor
to ESRD in most patients), the only recent introduction
of precise epidemiologic and clinical definitions of CKD
and the relatively high mortality rate of this group of pa-
tients. It is therefore highly probable that the number of
patients with ESRD underestimates the entire burden of
CKD, because the numbers with earlier stages of disease
(stages 1 to 4) are likely to exceed by as much as 50 times
those reaching stage 5 (ESRD) according to the United
States Kidney Foundation’s Kidney Disease Outcomes
Quality Initiative (KDOQI) [5].
EPIDEMIOLOGY OF CKD OUTSIDE EUROPE
The limited amount of available data, mainly de-
rived from registries in the United States, suggests that
CKD is also a significant epidemiologic problem in the
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Table 1. Incidence and prevalence of RRT in countries and regions
included in the ERA-EDTA Registry (source ERA-EDTA
Registry—Annual Report 2002)
Prevalence
Incidence at of RRT on
day 1 of December 31
RRT (pmp) (pmp)
Austria 131 781
Belgium, Dutch-speaking 170 882
Belgium, French-speakinga 170 802
Bosnia-Herzegovina 110 400
Croatia 118 699
Czech Republic 172 695
Denmark 129 711
Estonia — 273
Finland 92 636
France, Limousin 177 810
France, Lorraine 148 822
Germany 174 918
Greece 165 841
Iceland 77 438
Latvia 59 266
Macedonia 73 522
Norway 93 641
Poland 99 405
Portugal 200 1097
Russia 15 79
Serbia and Montenegro 137 493
Slovakia 139 488b
Spain, Basque country 99 893
Spain, Catalonia 147 1018
Spain, Valencia region 155 1081
Sweden 125 759
The Netherlands 100 658
Tunisia 112 539
UK, England, Wales 95 601
UK, Scotland 108 700
25 European Union 137 786
countries (estimate)
Abbreviations are: RRT, renal replacement therapy; ERA-EDTA, European
Renal Association/European Dialysis and Transplant Association Registry;
pmp, per million population.
aBased on 2001 data.
bDialysis patients only.
stages before RRT. The Third National Health and Nutri-
tion Examination Survey (NHANES III), collecting data
among a large representative sample of the United States
population (18,723 participants of different age, sex, and
ethnic groups examined between 1988 and 1994), still rep-
resents the most comprehensive source of epidemiologic
data regarding CKD in the conservative phase [6]. This
survey estimated that up to 11% of the general adult pop-
ulation (19 million) could have some degree of CKD, in-
cluding more than 8 million individuals with glomerular
filtration rates (GFR) of less than 60 mL/min [5]. The
percentage of the overall United States population with
serum creatinine (SCr) values >1.5 mg/dL was 9.74% in
men and 1.78% in women; it was also found that older age,
together with male sex, was associated with higher SCr
levels. More than 30% of men and nearly 10% of women
aged >70 years were estimated to have SCr levels >1.5
mg/dL in this survey [6]. This analysis also estimated that
5.9 million people could have stage 1 CKD with normal
renal function [5].
A recent article by Coresh et al [7] quantifies the pool
of CKD patients in 1999 to 2000 and compares it with that
in 1988 to 1994. It was found that the prevalence of mod-
erately or severely decreased kidney function (GFR 15
to 59 mL/min per 1.73 m2) remained stable over the past
decade (4.4 ± 0.3% in 1988 to 1994 and 3.8 ± 0.4% in 1999
to 2000). At the same time, the prevalence of albuminuria
(albumin to creatinine ratio (ACR) ≥30 mg/g) in single
spot urine significantly increased from 8.2 ± 0.4% to 10.1
± 0.7%. Overall CKD prevalence was similar in both
surveys (9% using ACR >30 mg/g for persistent microal-
buminuria; 11% in 1988 to 1994, and 12% in 1999 to 2000
using gender-specific ACR cutoffs). In contrast to the
dramatic increase in treated kidney failure, overall CKD
prevalence in the US population has been relatively sta-
ble. The estimated prevalence of ESRD (KDOQI stage
5) in the US population is 344,000 [8]. This could suggest
that less than 2% of the US CKD population progresses
to RRT. Relatively little is known about the 98% of pa-
tients with CKD who do not advance to ESRD or are
not taken into RRT. However, in 1996, the Kaiser Per-
manente health plan identified 27,998 patients with an
estimated GFR of less than 90 mL/min/1.73 m2 on two
separate measurements at least 90 days apart [9]. The pa-
tients were followed up from the index date of the first
GFR of less than 90 mL/min per 1.73 m2 until RRT, death,
disenrollment from the health plan, or June 30, 2001. The
data showed that the rate of RRT over the 5-year obser-
vation period was 1.1%, 1.3%, and 19.9%, respectively,
for the KDOQI stages 2, 3, and 4, but that the mortality
rate was 19.5%, 24.3%, and 45.7% for the same stages.
During this observation period, it appeared thus that only
3.1% of patients with stage 2 through stage 4 disease pro-
gressed to RRT, while 24.9% died. Thus, death was far
more common than dialysis at all stages. In other words,
these data indicate that RRT patients in registries are not
representative for patients with CKD [9].
In the United States, the Kidney Early Evaluation Pro-
gram was a free, community-based screening that took
place in 21 cities in 1997. The objective was to identify per-
sons at risk for kidney disease by screening persons with
first-order relatives with diabetes, hypertension, or kid-
ney disease, or those with a personal history of diabetes or
hypertension [10] Six hundred thirty-six (71.4%) of the
889 screened individuals had abnormal test values and
were encouraged to follow-up. Three hundred ninety-
four individuals (44.3%) had two or more values outside
the normal range, and 514 (57.8%) learned of at least
one new condition. There were 420 individuals identified
with markers for kidney disease, some of whom had more
than one abnormality: 114 had an elevated SCr, 171 had
microalbuminuria, 137 had pyuria, and 165 had hema-
turia. From this preliminary report, it was concluded that
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targeted screenings are an effective means of identifying
persons at risk for kidney disease, and can identify indi-
viduals at risk early enough in the course of their disease
to allow for effective intervention
The interpretation of the epidemiologic data on CKD
in the United States has been subject to some debate.
Clase et al [11] applied four equations that predict GFR
from measurements of SCr, with SCr values obtained in
13,251 normal, nondiabetic adults in the NHANES III.
They arrived at the rather startling conclusion that CKD
was as much as a log factor more common than previ-
ously predicted; for example, 13% of the population had
GFR below 60 mL/min/1.73 m2, and these figures were
significantly higher in the elderly. Clase et al conclude
by recommending that predictive equations to calculate
GFR should not be routinely applied by laboratories that
measure SCr until further research is done to determine
the meaning of their observations. The authors reported
a prevalence of reduced GFR that is approximately five-
fold greater than previous estimates. In a worst-case
scenario, their results suggest that approximately half
of the ambulatory, adult US population have a reduced
GFR. If this assessment of the prevalence of CKD is
valid and all of these patients survived to develop ESRD,
the American health care system would be financially
overwhelmed.
The prevalence of CKD in the study by Clase et al
[11] contradicts that reported in the KDOQI. [12]. Us-
ing NHANES III, the KDOQI group estimated that
64% of US adults aged 20 years or older had an esti-
mated GFR ≥90 mL/min by the Modification of Diet
in Renal Disease (MDRD) equation. Only 31% of the
population was estimated to have a GFR between 60
and 89 mL/min, and 4.3% with a GFR between 30 and
59 mL/min. Conversely, the KDOQI group noted that
only 0.2% of the population had an estimated GFR of
2 mg/dL versus >1.5 mg/dL [12]. Many of the epidemi-
ologic studies on prevalence of CKD did not take into
account two important sources of bias (i.e., the lack of
standardized serum creatinine methodology and the age-
related decline in renal function) [13–33]. Performing an
age-stratified analysis, Jungers et al recorded a striking
increase in the annual incidence of CKD together with
the increase of age, with incidence rates in patients aged
>75 years being almost seven times higher than those of
patients aged 20 to 39 years (619 per million population
[pmp] vs. 92 pmp) and more than twice those of patients
aged 40 to 59 years (619 pmp vs. 264 pmp) [32]. In a
recent Italian regional epidemiologic analysis, in which
data were collected from the local dialysis and transplan-
tation registry, hospital discharge abstracts, and ambula-
tory and laboratory databases, the prevalence of patients
with CKD (defined as SCr >1.5 mg/dL) was estimated
to be about 0.8% of the general population, with 75% of
these patients being unknown by nephrologists [34].
A more recent Italian study [35] analyzed the pres-
ence of overnight urinary albumin excretion with preva-
lence of coronary heart disease and low renal function in
a population sample of 1632 men and women aged 45 to
64 years. Coronary heart disease prevalence was 8.2%
in the whole sample. Prevalence of low renal function
was 4% in the total group, and 4.8% in the hyperten-
sive group. Age-related incidence rose from 58 pmp per
year in those aged 20 to 49 years to 588 pmp per year
in those aged 80 years or older. Only 54% of these pa-
tients were referred to a nephrologist; 120 patients (57%)
needed dialysis or died within three months of presenting
without receiving dialysis, and 187 (89%) died or needed
dialysis within three years. After patients unsuitable for
further treatment had been excluded, the authors calcu-
lated that 78 patients pmp per year younger than 80 years
of age needed to start long-term RRT.
In a Spanish general population study, it was found
that the prevalence of stages 2 and 3 CKD increased with
age (especially > 65), and this more in women than in
men. Using the Cockroft-Gault method, almost half the
older women had a stage 3 CKD as opposed to a third
of the men, whereas if the abbreviated MDRD study was
used, there were very few differences between the sexes.
This difference was most pronounced in stage 2 (60% as
opposed to 36%) [36].
Khan et al [39] calculated an annual incidence of
chronic renal failure (CRF) (SCr ≥300 lmol/L) as 450
pmp, and persistent advanced CRF (SCr ≥500 lmol/L) as
132 pmp. After excluding those aged >80 years and those
with advanced malignancy, the corresponding incidence
figures were 240 pmp per year and 81 pmp per year. Only
109 patients (35.8%) were referred to a nephrologist.
In the Southampton and Southwest Hampshire Health
Authority population base of 405,000, a retrospective co-
hort analysis was performed on all new cases of CKD de-
termined by a persistently increased SCr level≥1.7 mg/dL
for 6 months, identified from chemical pathology records
[40]. The annual incidence rate of detected CKD was
1701 pmp and 1071 pmp in those younger than 80 years.
The median survival was 35 months. Only 4% of patients
were accepted to RRT.
John et al [41] identified patients in a predominantly
Caucasian UK population who were unknown to renal
services, and followed up with them to establish survival,
rate of referral, and change in GFR. The prevalence of
CKD defined by SCr cutoff values of ≥2.03 mg/dL in
men and ≥1.53 mg/dL in women was 5554 pmp. Median-
calculated GFR of the cohort was 28.5 mL/min/1.73 m2,
and median age was 83 years. A total of 84.8% of patients
were unknown to renal services. During a mean follow-
up of 31.3 months, 8.1% of these patients were referred.
The median survival of the unreferred population was
28.1 months. The majority of unreferred patients had sta-
ble renal function. The incidence of new unreferred CKD
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during the first year of follow-up was 2435 pmp, such that
the prevalence remained stable at 4910 pmp. It was con-
cluded that referral of all patients with CKD is unrealistic
and inappropriate. Management strategies aimed at im-
proving adverse outcomes need to take account of this
and be developed and implemented through collabora-
tion between primary and secondary health care services.
It is generally believed that once CRF is established,
it progresses to ESRD irrespective of its original cause.
However, longitudinal data on the natural course of CRF
are sparse.
One of the few studies to evaluate the prevalence of
CRF in an unselected population and look into the prob-
lem of progression of kidney disease has recently been
performed in Iceland [42]. The study sample comprises a
large fraction of the Icelandic population, which totaled
286,275 individuals on December 1, 2001. The authors
studied 18,912 adult patients between 1967 and 1991. Pa-
tients with SCr levels of ≥1.7 mg/dL were considered to
have CRF. The crude prevalence of CRF, as well as age-
standardized prevalence for 5-year age groups, was de-
termined. Progression of CRF was defined as a decrease
in estimated GFR greater than 1 mL/min/1.73 m2/year.
Of 49 individuals who had an SCr of ≥1.7 mg/dL at en-
try, 41 individuals had a persistent elevation in SCr lev-
els. Thirty-four individuals had mild CRF (SCr, 1.7 to
2.8 mg/dL), 6 individuals had moderate CRF (SCr, 2.8
to 5.6 mg/dL), and 1 individual had ESRD. The crude
prevalence of CRF was 0.22%; 0.15% among women and
0.28% among men. Only 27 patients had progressive re-
nal failure, 17 of whom progressed to ESRD during a
median of 7 years (range, 3 to 21 years). It was concluded
that the prevalence of CRF is markedly low in Iceland
and that 27% of patients did not show progression of their
renal failure during a median of 11 years of follow-up.
The definition of progression used in the Icelandic
study as a decline in estimated GFR in excess of 1
mL/min/1.73 m2/year is somewhat arbitrary. It is based
on traditional beliefs that an age-related decline in GFR
may be as high as 1 mL/min/1.73 m2/year [43]. Four of
the eight patients in the Icelandic study with an estimated
GFR decline between 1 and 2 mL/min/1.73 m2/year devel-
oped ESRD, which suggests that with time, a significant
number of patients with such a modest decline in renal
function are at risk for developing ESRD. It is of inter-
est to note that the majority of patients with an unknown
cause of CRF did not progress. Their indolent course may
have led to a more conservative approach to their man-
agement, so that diagnostic procedures were not pursued.
Data on the incidence of ESRD and CRF from
population-based studies in Caucasian type 2 diabetic
patients are lacking. To provide such data, a population-
based cohort of type 2 diabetic patients was identified
in Casale Monferrato, Italy, and prospectively examined
from 1991 to 2001 [44]. The authors followed up 1408 of
1540 (91.4%) patients (average follow-up time 6.7 years);
10 new cases of ESRD and 72 of CRF (plasma values of
creatinine ≥2.0 mg/dL) were identified, giving incidence
rates per 1000 persons per year of 1.04 and 7.63, respec-
tively. Cumulative risks for CRF adjusted for competing
mortality were 6.1% and 9.3% after 20 and 30 years from
diagnosis of diabetes, respectively. Incidence rates and cu-
mulative risks of CRF defined by plasma creatinine values
>1.5 mg/dL increased to 13.1 per 1000 persons per year,
8.6% and 14.8%, respectively. It was concluded that the
individual risk of ESRD and CRF in type 2 diabetes is
low, and that albumin excretion rate and diastolic blood
pressure are independent predictors of progression.
In the outpatient diabetic care unit of the University of
Torino (Italy), approximately 25% of the type 2 diabetics
of a 900,000-inhabitant city were followed up [45]. At the
time of the study (1998–1999), the unit followed up with
5182 type 2 diabetics whose SCr and proteinuria were
tested at least yearly. A total of 3826 prevalent and 478
incident patients with one or more analyses in the same
laboratory were included in the study. The authors also
calculated the stepwise need for nephrologic follow-ups
calculated according to their usual policy (4–12 evalua-
tions per year on SCr and proteinuria and 30 minutes per
evaluation). The prevalence of increased SCr ≥1.5 mg/
dL was 8.1%; of proteinuria 0.3 g/day was 25.2%; of SCr
≥3 mg/dL was 1.2%; and of nephrotic proteinuria, it was
3.4%). Projecting this data to the entire unit, with adher-
ence to their usual evaluation protocol, it was estimated
that early nephrologic follow-up of type 2 diabetics would
require approximately 1300 hours per year (one full-time
nephrologist); 5 nephrologists would be needed for the
whole city of Torino, and 24 nephrologists would be re-
quired for the region of 4,350,000 inhabitants. It was con-
cluded that early nephrologic referral and follow-up of
type 2 diabetics is time-consuming, expensive, and that
meeting this type of outpatient care requires consider-
able resources.
Population-based programs to promote screening for
CKD are intended to increase the rate that persons with
previously undetected renal injury are identified and
linked to further evaluation and disease-modifying in-
tervention [46].
It is the expectation that early intervention for pa-
tients with CKD will delay, if not prevent, subsequent
progression to ESRD. There are interventions to delay
and prevent the progression of CRF [47–71], and national
guidelines have recommended that all patients with ev-
idence of reduced renal function (e.g., SCr level >1.7
mg/dL or GFR 60 mL/min/1.73m2) should be sent to a
nephrology unit when these values are confirmed at the
second evaluation. In multivariate analysis, urinary albu-
min excretion was independently predictive for the risk of
developing an impaired GFR [72]. Measurement of uri-
nary albumin excretion may thus prove to be a valuable
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Table 3. Population-based study of the epidemiology of CKD in Belgium and the mortality in the different stages of CKD, with results based on
MDRD staging (mL/min/1.73m2), and on Cockroft-Gault staging (mL/min)
Total number % Total Total number % CVD Total number % CHD
of individuals mortality of individuals mortality of individuals mortality
GFR
>60 7630 6.6 7267 1.98 7198 1.04
30–60 1458 12.2 1345 4.8 1323 3.3
15–30 16 25 13 7.7 13 7.7
<15 2 50 2 50 2 50
Creatinine clearance
>60 7816 5.8 7494 1.72 7439 0.99
30–60 1259 18.4 1105 7.1 1069 3.9
15–30 17 41.2 14 28.6 14 28.6
<15 0 — 0 — 0 —
Abbreviations are: CKD, chronic kidney disease; CHD, coronary heart disease; MDRD, Modification of Diet in Renal Disease (study); GFR, glomerular filtration
rate. Mortality is given as total mortality, CVD mortality, and mortality due to CHD 10 years after screening.
tool to detect patients at risk for later development of
renal failure, independent of the presence of other car-
diovascular risk factors.
A preliminary analysis of the distribution of CKD in
a population study in Belgium has recently been per-
formed, and the data are summarized in Table 3. The re-
sults are based on observations made in men and women
who took part in the Belgian inter-university research on
nutrition and health study. This study, in which baseline
measurements were made in the years 1981 to 1984, fo-
cuses on the distribution of cardiovascular risk factors
and nutritional habits in Belgium and their relation to to-
tal and cause-specific mortality. An age- and sex-stratified
population sample of patients 25 to 74 years of age was
selected at random from 42 of the 43 Belgian geographic
districts. To achieve a sufficient sample size under cir-
cumstances in which little pressure was put on invited
eligible patients, a sample of more than 30,000 persons
was selected. The participation rate was 36.5%, resulting
in 11,302 patients taking part in the study (5949 men and
5353 women). A 10% random sample of nonparticipants
was selected and invited to answer a number of ques-
tions related to smoking and nutritional habits, which re-
vealed that no differences existed between participants
and nonparticipants with respect to lifestyle. GFR was
estimated by both the simplified MDRD formula or by
Cockcroft-Gault (CG) formula. This population database
also contains information on the evolution of mortality
10 years after the initial screening. For all participants,
biochemical measurements were performed with a non-
fasted blood sample analyzed in one central laboratory.
Levels of SCr were measured on an SMAC Technicon
(Technicon Instruments Corp, Tarrytown, NJ, USA).
Table 3 shows the 10-year total mortality and mortal-
ity due to cardiovascular diseases in the different stages
of CKD based on the CG and MDRD estimated GFR.
Although there was a prevalence of a GFR >60 mL/min
by CG and MDRD of 84.3% and of 83.2% of the stud-
ied population, respectively, total cardiovascular disease
mortality and mortality due to coronary heart disease
increased inversely with the estimated GFR, which con-
firmed recent results obtained from the Hoorn Study [73]
in the Netherlands and Go et al [74] in the United States.
It has been shown that the prevalence of CKD in-
creases to 50% to 60% when at-risk individuals are
screened [10], and the early identification of such indi-
viduals and prevention of progressive CKD are likely to
be key factors in alleviating the future burden of ESRD
and its associated mortality.
HIGH-RISK SCREENING OR
POPULATION-BASED INTERVENTION
STRATEGIES?
Although there is no well-defined method of identify-
ing “high-risk” populations, the KDOQI guidelines iden-
tify demographic groups characterized by high incidence
or prevalence of CKD as populations that should be tar-
geted for screening and intervention [12]. Note that simi-
lar high-risk disease control strategies for cardiovascular
disease have been criticized. Rose et al have argued that
most cases of cardiovascular disease arise not from the
“high-risk” tail of the population but from the general
population [75, 76], and a similar situation may pertain
to ESRD.
Are there populations of patients wherein the practi-
cality of a population-based screening strategy for CKD
might be easily studied? Two studies have recently re-
ported suggesting this possibility [77, 78]. These studies
involve family members of patients with ESRD and pa-
tients who are hospitalized for cardiovascular problems.
Family members of ESRD patients were recruited for
CKD screening. Of 221 family members of patients with
ESRD screened between 1999 and 2001, 13.9% had an
estimated creatinine clearance of 2.0 mg/dL. These results
indicate that CKD is both prevalent among patients with
congestive heart failure and confer substantial increased
risk of mortality in this population.
COST-EFFECTIVENESS ANALYSIS
The cost-effectiveness of screening is one of the most
relevant criteria for advocating systematic screening for
S-36 Lameire et al: CKD: A European perspective
renal disease. Unfortunately, extremely limited data on
the cost, as well as the effect of the early detection of renal
disease, are available. Indeed, the few publications that
have attempted to address this issue have used computer
simulation models, rather than performing randomized
clinical trials evaluating the efficacy of systematic screen-
ing. In addition, the majority of these analyses are limited
to studying the efficacy of microalbuminuria screening in
the context of the prevention of diabetic nephropathy.
For example, a recent review by Scheid et al [79] iden-
tified seven such cost-effectiveness analyses, only two of
which focused on type 2 diabetes mellitus [80, 81]. In
both these analyses, screening for microalbuminuria ap-
peared to be a cost-effective approach. However, it was
the systematic treatment of all newly diagnosed patients
with type 2 diabetes mellitus that appeared to be most
associated with the highest life expectancy, as illustrated
by a marginal cost-effectiveness ratio of US $7500 per
quality-adjusted life year gained when all patients were
treated with angiotensin-converting enzyme (ACE) in-
hibitors compared with systematic screening for microal-
buminuria [81]. It was further argued that the routine
treatment of all patients with type 2 diabetes mellitus
using ACE inhibitors would potentially bypass current
concern for low rates of microalbuminuria screening by
primary care physicians. However, these analyses were
limited by strict assumptions as to the efficacy of ACE
inhibitors in preventing the progression of normoalbu-
minuria to microalbuminuria. Furthermore, the marginal
cost-effectiveness ratio was extremely sensitive to factors
such as age at diagnosis of diabetes mellitus, cost of ACE
inhibitors, and side effects of the chronic use of these
drugs.
In the only analysis evaluating the cost-effectiveness of
screening for nondiabetic renal disease, Craig et al [67]
recently questioned the feasibility of mass screening for
detection of CKD based on Australian data. ESRD devel-
ops in about 1500 Australians each year. Of these, about
1000 are more than 50 years of age (an incidence of about
200 pmp per year). Proteinuria, which is present in about
5% of the general population, confers an approximately
15-fold increased risk for ESRD. Twelve randomized tri-
als of ACE inhibitors, in 1943 patients with varying de-
grees of renal impairment, hypertension, and proteinuria,
showed that the risk of developing ESRD can be reduced
by about 30% over a 2- to 3-year period. In a general
practice-based screening model involving: (1) an oppor-
tunistic single dipstick test for protein, (2) a confirming
24-hour urine test for protein, and (3) commencement of
ACE inhibitors in appropriate individuals, 20,000 people
50 years of age or older would need to be screened to pre-
vent one case of ESRD. To achieve this, approximately
100 people would need to be treated with ACE inhibitors
for 2 to 3 years, and 1000 would need to have a 24-hour
urine protein test (and, of these, 700 would be false posi-
tives). Such a strategy may save health dollars, but some
critical research questions are still unanswered. What is
an individual’s risk of developing ESRD, given values for
proteinuria, blood pressure, and renal function? What is
the benefit of ACE inhibitors in screen-detected cases,
which are at low risk of ESRD? What psychologic and
physical harm is caused by screening, including the spe-
cific renal investigations and treatments that follow pro-
teinuria detection?
The authors concluded that given available data,
screening middle-aged and older Australians for protein-
uria and treating some with ACE inhibitors is, at best,
a promising primary prevention strategy for preventing
ESRD. However, a large population-based cohort study,
with nested trial of ACE inhibitors, is still required to
evaluate whether this model of screening for renal dis-
ease does more harm than good [67].
However, this analysis, as in other simulation models, is
subject to the limitations of the model assumptions such
as those the authors made regarding the reliability and
reproducibility of screening tools and the natural history
of renal disease progression. Indeed, the authors note un-
certainty about the risk of progression to ESRD among
patients with proteinuria, the risks and benefits of ACE
inhibitor therapy among patients at low risk for ESRD,
and the adverse psychologic and physical consequences
of the screening process. Thus, although these indirect
evaluations of the effectiveness of screening with simu-
lation models suggest its usefulness, these findings only
emphasize the dearth of definitive studies that examine
the effectiveness of screening for renal disease.
CONCLUSIONS
This article summarizes the scarce information on the
epidemiology of CKD before stage 5 in Europe. From
the data available, we can derive that the prevalence of
undetected (or unreferred) CKD in our continent is at
least as high as in the United States.
In addition, the utility of screening for patients at risk
of CKD is briefly discussed.
People with hypertension, diabetes, cardiovascular dis-
ease, autoimmune disease, and their family members are
at high risk and should be screened by urinalysis and by
testing for SCr. Conversely, the utility of unselected popu-
lation screening for renal disease (e.g., by dipstick) is very
low [82, 83] and should at present not be recommended.
The use of estimating GFR by the available equations
should be limited to identifying patients with low GFR
[5], although there are compelling arguments against
this recommendation [11]. Applying estimating equa-
tions universally will lead to the “labeling” and referral of
many patients who would not otherwise have been identi-
fied as having renal failure. These patients will have differ-
ent demographic characteristics (older age, more women,
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higher proportion with nonproteinuric renal disease) and
probably a lower risk of progression than those identified
on the basis of SCr level [5, 11]. The benefits of nephro-
logic intervention in such patients are unclear. Moreover,
current nephrology resources could not possibly handle
the potential referrals [84]. A clinical trial is urgently
needed to address whether referral triggered by iden-
tification of low estimated GFR leads to cost-effective
therapy. In the absence of clear evidence of benefit, it
may be premature to advocate a strategy with such ma-
jor resource implications.
Reprint requests to Norbert Lameire, Renal Division, Department of
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